MEDNAX (MD) Tops Q4 EPS by 8c; Issues 2022 EBITDA Guidance

MEDNAX (NYSE: MD) reported Q4 EPS of $0.52, $0.08 better than the analyst estimate of $0.44. Revenue for the quarter came in at $499 million versus the consensus estimate of $483.83 million.

On a preliminary basis, Mednax anticipates that its 2022 Adjusted EBITDA, as defined above, will be at least $270 million.

For earnings history and earnings-related data on MEDNAX (MD) click here.

You May Also Be Interested In

• Are we witnessing a fundamental or speculative rally in the S&P 500?
• Morgan Stanley backs Yum Brands, cuts Chipotle rating as growth outlook diverges
• Fairfax prices $750 million senior notes offering at 6.200% interest